Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor
- Authors: Ganshina I.P.1, Ivanova K.A.1, Lubennikova E.V.1, Arkhipov A.V.2, Zhukova L.G.3
-
Affiliations:
- Blokhin National Medical Research Center of Oncology
- National Medical Research Center of Treatment and Rehabilitation
- Loginov Moscow Clinical Scientific Center
- Issue: Vol 22, No 4 (2020)
- Pages: 86-90
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/61161
- DOI: https://doi.org/10.26442/18151434.2020.4.200510
- ID: 61161
Cite item
Full Text
Abstract
Breast cancer is still the leading cause of death in patients with malignant tumors. Among women with breast cancer, standard combination chemotherapy with anthracyclines and taxanes reduces mortality from this disease by about one third compared to patients not receiving chemotherapy and is the standard for neoadjuvant or adjuvant chemotherapy of breast cancer. Understanding the patterns of tumor growth has made it possible to improve the current paradigms of the treatment of early forms of breast cancer and to use dose-dense chemotherapy regimens to achieve better treatment results. Nowadays, chemotherapy in a dose-dense regimen for breast cancer is the preferred option in all world and Russian clinical guidelines. However, the use of such chemotherapy regimens significantly increases the incidence of side effects, primarily febrile neutropenia. The appearance of more effective methods of supportive care, particularly short-acting and long-acting granulocyte colony-stimulating factor, in clinical practice has made it possible to use dose-dense chemotherapy regimens to increase the effectiveness of the treatment.
Full Text
##article.viewOnOriginalSite##About the authors
Inna P. Ganshina
Blokhin National Medical Research Center of Oncology
Author for correspondence.
Email: ganshinainna77@mail.ru
ORCID iD: 0000-0002-0105-9376
Cand. Sci. (Med.)
Russian Federation, MoscowKristina A. Ivanova
Blokhin National Medical Research Center of Oncology
Email: ivanova_ka7@mail.ru
ORCID iD: 0000-0001-7087-2435
Clinical Resident
Russian Federation, MoscowElena V. Lubennikova
Blokhin National Medical Research Center of Oncology
Email: lubennikova@yandex.ru
ORCID iD: 0000-0001-5289-7866
Cand. Sci. (Med.)
Russian Federation, MoscowAlexandr V. Arkhipov
National Medical Research Center of Treatment and Rehabilitation
Email: a.arkhipov75@mail.ru
ORCID iD: 0000-0002-2921-5692
Cand. Sci. (Med.)
Russian Federation, MoscowLiudmila G. Zhukova
Loginov Moscow Clinical Scientific Center
Email: zhukova@mknc.ru
ORCID iD: 0000-0003-4848-6938
D. Sci. (Med.), Prof. RAS
Russian Federation, MoscowReferences
- Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2019 году. М., 2020. [Kaprin A.D., Starinskii V.V., Shakhzadova A.O. The state of cancer care for the population of Russia in 2019. Moscow, 2020 (in Russian).]
- Peto R, Davies C, Godwin J et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 432–44.
- Available from: https://ascopost.com/issues/october-15-2013/dr-larry-norton-honored-at-2013-breast-cancer-symposium-calls-for-a-return-to-the-exploration-of-concepts/
- Mayordomo JI, López A, Viñolas N et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 2009; 25 (10): 2533–42. doi: 10.1185/03007990903209563
- Kuderer NM, Dale DC, Crawford J et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106 (10): 2258–66. doi: 10.1002/cncr.21847
- Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332 (14): 901–6. doi: 10.1056/NEJM199504063321401
- Bonadonna G, Moliterni A, Zambetti M et al. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005; 330 (7485): 217. doi: 10.1136/bmj.38314.622095.8F
- Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther 2003; 1 (1): 23–35. doi: 10.3816/SCT.2003.n.002
- De Miguel SC et al. Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia. Supportive Care in Cancer 2015; 23 (2): 547–59.
- Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47 (1): 8–32. doi: 10.1016/j.ejca.2010.10.013
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393 (10179): 1440–52. doi: 10.1016/S0140-6736(18)33137-4
- Ding Y, Ding K, Yang H et al. Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients. PLoS One 2020; 15 (5): e0234058. doi: 10.1371/journal.pone.0234058
- Bonilla L, Ben-Aharon I, Vidal L et al. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 2010; 102 (24): 1845–54. doi: 10.1093/jnci/djq409
- Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431–9.
- Del Mastro L, De Placido S, Bruzzi P et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2×2 factorial, randomised phase 3 trial. Lancet 2015; 385: 1863–72.
- Venturini M, Del Mastro L, Aitini E et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 2005; 97: 1724–33.
- Foukakis T, von Minckwitz G, Bengtsson NO et al. Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial. JAMA 2016; 316: 1888–96.
- Mobus V, Jackisch C, Luck HJ et al. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol 2018; 29: 178–85.
- Waks AG, Tolaney SM, Galar A et al. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat 2015; 154: 359–67.
- Pathak R, Giri S, Aryal MR et al. Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States. Support Care Cancer 2015; 23 (3): 615–7.
- Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009; 7 (1): 99–108.
- Muss HB, Woolf S, Berry D et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005; 293: 1073–81.
- Lyman GH, Dale DC, Culakova E et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013; 24: 2475–84.
- Klastersky J, de Naurois J, Rolston K et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Annals of Oncology 2016; 27 (Suppl. 5): v111–v118. doi: 10.1093/annonc/mdw325
- Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24 (19): 3187–205. doi: 10.1200/JCO.2006.06.4451
- Weycker D, Barron R, Edelsberg J et al. Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Serv Res 2014; 14: 189. doi: 10.1186/1472-6963-14-189
- Clemons M, Fergusson D, Simos D et al. A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. Annals of Oncology 2020; 31 (7): 951–7. doi: 10.1016/j.annonc.2020.04.005
- Green MD, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14 (1): 29–35. doi: 10.1093/annonc/mdg019
- Holmes FA, O’Shaughnessy JA, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20 (3): 727–31. doi: 10.1200/JCO.2002.20.3.727
- Кононенко И.Б., Снеговой А.В., Гребенникова О.П. и др. Роль пролонгированных гранулоцитарных колониестимулирующих факторов в профилактике фебрильной нейтропении у пациентов, получающих двухнедельные режимы химиотерапии. Современная онкология. 2020; 22 (3): 133–41. [Kononenko I.B., Snegovoy A.V., Grebennikova O.P. et al. Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy. Journal of Modern Oncology. 2020; 22 (3): 133–41 (in Rissian).]. doi: 10.26442/18151434.2020.3.200279
- Mitchell S, Li X, Woods M et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review. J Oncol Pharm Pract 2016; 22 (5): 702–16. doi: 10.1177/1078155215625459
- Kosaka Y, Rai Y, Masuda N et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 2015; 23 (4): 1137–43. doi: 10.1007/s00520-014-2597-1
- Cornes P, Gascon P, Chan S et al. Systematic Review and Meta-analysis of Short-versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia. Adv Ther 2018; 35 (11): 1816–29. doi: 10.1007/s12325-018-0798-6
- Papakonstantinou A, Hedayati E, Hellström M et al. Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. Acta Oncologica 2020; 59 (1): 75–81. doi: 10.1080/0284186X.2019.1670353
- Криворотько П.В., Бурдаева О.Н., Нечаева М.Н. и др. Эффективность и безопасность препарата Экстимия® (эмпэгфилграстим) у пациентов с диагнозом «рак молочной железы», получающих миелосупрессивную химиотерапию: результаты двойного слепого сравнительного клинического исследования III фазы. Современная онкология. 2015; 17 (2): 45–52. [Krivorotko P.V., Burdaeva O.N., Nechaeva M.N. et al. Efficacy and safety of Extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis “breast cancer” receiving myelosuppressive chemotherapy. Journal of Modern Oncology. 2015; 17 (2): 45–52 (in Russian).]
- Barcenas CH, Niu J, Zhang N et al. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol 2014; 32 (19): 2010–7. doi: 10.1200/JCO.2013.49.3676
- Zauderer M, Patil S, Hurria A. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat 2009; 117 (1): 205–10. doi: 10.1007/s10549-008-0116-0
- Potosky LA, Malin JL, Kim B et al. Use of Colony-Stimulating Factors With Chemotherapy: Opportunities for Cost Savings and Improved Outcomes. JNCI 2011; 103 (12): 979–82.
- Pietri E, Andreis D, Fabbri F et al. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer. The Oncologist 2015; 20 (3): 239–40. doi: 10.1634/theoncologist.2014-0326
- Rossi L, Tomao F, Lo Russo G et al. Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. Ther Clin Risk Manag 2013; 9: 457–62. doi: 10.2147/TCRM.S48387
- Schnipper LE, Smith TJ, Raghavan D et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012; 30 (14): 1715–24. doi: 10.1200/JCO.2012.42.8375